RxDoctor Payments Data

Anthony Brown, MD

Neurology · Fort Myers, FLNPI 1144486770

Payments from drug & device makers

$21,818in general payments, 2019–2025

Across 1,047 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Lundbeck LLC$1K
  • AstraZeneca$1K
  • Amgen$1K
  • Acadia Pharmaceuticals Inc$1K
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$390%
  • Travel & lodging$120%
  • Food & beverage$21,54499%
  • Education$2231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)160$2,916
UCB, Inc.58$1,667
Lundbeck LLC58$1,431
AstraZeneca(2 entities)55$1,243
Amgen(2 entities)55$1,223
Acadia Pharmaceuticals Inc53$1,080
GE HealthCare38$702
Novartis36$692
Teva Pharmaceuticals USA, Inc.37$594
Merz Pharmaceuticals, LLC19$507
Genentech USA, Inc.29$488
Argenx US, Inc.19$448
Lilly USA, LLC26$430
Biohaven Pharmaceutical Holding Company Ltd.21$423
Sanofi18$405
CSL Behring18$375
Pfizer22$367
Neurocrine Biosciences, Inc.20$349
Biogen18$347
Neurelis, Inc.19$315
SK Life Science, Inc.11$302
Acorda Therapeutics, Inc12$290
MDD US Operations, LLC16$289
Takeda Pharmaceuticals U.S.A., Inc.10$284
Amneal Pharmaceuticals LLC10$281
Bristol Myers Squibb13$268
Eisai Inc.12$267
Biohaven Pharmaceuticals, Inc.12$249
EMD Serono, Inc.11$235
Alnylam Pharmaceuticals Inc.10$216
Revance Therapeutics, Inc.4$201
Octapharma USA, Inc.3$194
Scilex Pharmaceuticals Inc.8$186
Upsher-smith Laboratories LLC11$183
Johnson & Johnson(2 entities)10$172
Catalyst Pharmaceuticals, Inc.8$169
Kyowa Kirin, Inc.9$161
TG Therapeutics, Inc.6$150
Grifols USA, LLC7$147
Otsuka America Pharmaceutical, Inc.7$132
Sunovion Pharmaceuticals Inc.8$131
Avion Pharmaceuticals7$111
Adamas Pharmaceuticals, Inc.6$110
Avanir Pharmaceuticals, Inc.7$103
E.r. Squibb & Sons, L.L.C.5$95
Almatica Pharma LLC5$87
Merz North America, Inc.4$76
Jazz Pharmaceuticals Inc.3$73
HEMA Biologics, LLC4$66
Corium, LLC2$47
Livanova USA, Inc.1$47
Aprecia Pharmaceuticals, LLC2$42
Medtronic2$42
Sumitomo Pharma America, Inc.2$40
Supernus Pharmaceuticals, Inc.2$40
Mallinckrodt Hospital Products Inc.2$40
Tanabe Pharma America, Inc.3$39
Impel Pharmaceuticals Inc.2$37
Ipsen Biopharmaceuticals, Inc2$34
Actelion Pharmaceuticals US, Inc.1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,818 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$1,298,854
Medicare patients
1,283
Services billed
62,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5057$643,573
GammakedImmune Globul G/Gly/Iga Avg 4636$460,539
FirdapseAmifampridine Phosphate11$293,392
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5048$272,636
Gamunex-CImmune Globul G/Gly/Iga Avg 4621$256,924
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5019$143,361
Avonex (4 Pack)Interferon Beta-1a12$115,184
Nurtec OdtRimegepant Sulfate37$61,115
Emgality PenGalcanezumab-Gnlm54$45,358
UbrelvyUbrogepant24$32,883
Ajovy AutoinjectorFremanezumab-Vfrm26$30,303
QuliptaAtogepant14$23,564
BotoxOnabotulinumtoxina13$17,650
ElyxybCelecoxib13$11,439
Rivastigmine55$10,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$367$704,68894 claims
Catalyst Pharmaceuticals, Inc.Firdapse$169$293,39211 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$284$272,63648 claims
Grifols USA, LLCGamunex-C$147$256,92421 claims
CSL BehringPrivigen$375$143,36119 claims
BiogenAvonex (4 Pack)$347$115,18412 claims
AbbVieUbrelvy, Qulipta, Botox$2,916$74,09751 claims
Scilex Pharmaceuticals Inc.Elyxyb$186$11,43913 claims
Upsher-smith Laboratories LLCTopiramate$183$2,092136 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$281$1,71018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →